Amylyx Pharmaceuticals, Inc. (AMLX) › Shareholders' EquityAmylyx Pharmaceuticals, Inc. (AMLX) — Shareholders' EquityAnnual figures by period end, from SEC filings.2020-12-31: -$66.72M2021-12-31: -$151.17M2022-12-31: $340.61M2023-12-31: $433.43M2024-12-31: $164.76M2025-12-31: $305.26M$305.26M2020-12-31Shareholders' Equity (USD)2025-12-31Period endedShareholders' EquityChange YoYSource filing2025-12-31$305.26M+85.3%2026-03-03Balance as of period end2024-12-31$164.76M-62.0%2026-03-03Balance as of period end2023-12-31$433.43M+27.3%2026-03-03Balance as of period end2022-12-31$340.61M—2025-03-04Balance as of period end2021-12-31-$151.17M—2024-02-22Balance as of period end2020-12-31-$66.72M—2024-02-22Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)